Latest news
Forlong advances IL-15 superagonist into Australian Phase I trial with subcutaneous dosing - AllSciAllSci · Wed, 05 Aug 2026 10:31:21 GMTForlong Biotechnology Announces Approval to Initiate Phase I Clinical Trial of FL115 (IL-15 Superagonist) Subcutaneous Injection in Australia - BioSpaceBioSpace · Wed, 05 Aug 2026 03:09:14 GMTForlong Biotechnology Announces Successful Completion of GMP Pivotal Batch Production for FL115 (IL-15 Superagonist), Ready to Support Upcoming Phase III Clinical Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) - Yahoo FinanceYahoo Finance · Mon, 03 Aug 2026 12:00:00 GMT